#Tecentriq

A personalized neoantigen vaccine from BioNTech and Roche/Genentech lowered the risk of relapse after surgery.

Patients who received atezolizumab (Tecentriq) plus bevacizumab (Avastin) had a 28% lower risk of cancer recurrence or death.

Tecentriq (atezolizumab) is the first drug approved approved for advanced alveolar soft part sarcoma, a rare cancer.

Cancer drugs called immune checkpoint inhibitors can cause itching and painful skin rashes. But what triggers these side effects?

A look back at some of the most important science and treatment news Cancer Health covered this year.

An advisory panel reviewed follow-up data on checkpoint inhibitors, voting to maintain four approvals and rescind two.

Tecentriq after surgery and chemotherapy delayed recurrence in people with Stage II or III non-small-cell lung cancer.

Treatment with Tecentriq plus Avastin or with Keytruda alone delays disease progression and improves survival.

Study offers assurance that the benefits of the combination can be achieved without diminishing patients’ quality of life.

Among urothelial cancer patients treated with atezolizumab, those who used PPIs had a 68 percent greater risk of death.

A Phase 1 study on customized immunotherapy shows promise for people with lung cancer.

A recent clinical trial found that the combination did not work.

Tecentriq plus two targeted medications extended progression-free survival by 4.5 months.

Combining a custom cancer vaccine and a checkpoint inhibitor generated tumor-specific immune responses in a majority of patients.

The combination improved both overall survival and patient-reported outcomes.